EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Multizentrische Studie

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004

William G Wierda iD, Kathleen Dorritie iD, Jordan Gauthier iD, Rajneesh Nath, Thomas J Kipps iD, Peter A Riedell iD, Herbert A Eradat, Saad S Kenderian, Mohamed A Kharfan-Dabaja iD, Nirav N Shah iD, Scott R Solomon, Deborah M Stephens und 27 weitere

Blood · 12.11.2026 · 148 (20) · 2462-2476

DOI: 10.1182/blood.2026033565 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Blood, erschienen am 12.11.2026. Verfasst von William G Wierda und 38 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Adenine, Immunotherapy, Adoptive, Leukemia, Lymphocytic, Chronic, B-Cell, Piperidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients in the lisocabtagene maraleucel (liso-cel) plus ibrutinib cohort of the phase 1/2, open-label TRANSCEND CLL 004 study had relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and received liso-cel (50 × 106 [dose level 1 (DL1)] or 100 × 106 [DL2] chimeric antigen receptor–positive T cells) with concurrent ibrutinib from enrollment through 90 days after liso-cel infusion or longer per investigator discretion. Primary end point was complete response/remission (CR)/CR with incomplete marrow recovery (CRi) by investigator assessment. Among 56 patients who received ibrutinib plus liso-cel (DL1, n = 5; DL2, n = 51), median age was 64.5 years (range, 44-77), 98% had high-risk cytogenetics, and median number of prior therapies was 5 (range, 1-13). Median follow-up was 24.8 months (range, 3.1-51.8). At DL2, CR/CRi rate was 45% (95% confidence interval [CI], 31-60), and overall response rate was 86% (95% CI, 74-94). Median duration of response was not reached (NR; 95% CI, 28.7 to NR) for patients with CR/CRi. Median progression-free survival was 31.4 months (95% CI, 20.1 to NR). In DL1 plus DL2, the most common grade ≥3 treatment-emergent adverse events (TEAEs) were neutropenia (52%) and anemia (41%). Cytokine release syndrome was reported in 80% of the patients (grade 3, 4%; no grade 4/5), and neurological events were reported in 41% (grade 3/4, 11%; no grade 5). Ibrutinib-related TEAEs were reported in 68% of the patients (grade 3/4, 43%; no grade 5). Liso-cel plus ibrutinib demonstrated notable efficacy in patients with R/R CLL/SLL with predictable and manageable safety. This trial was registered at www.clinicaltrials.gov as NCT03331198 and NCT03435796.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenineImmunotherapy, AdoptiveLeukemia, Lymphocytic, Chronic, B-CellPiperidinesReceptors, Chimeric AntigenAdultAgedFemaleHumansMaleMiddle Aged

Substanzen

AdenineibrutinibPiperidinesReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • The University of Texas MD Anderson Cancer Center, Houston, TX.
  • UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA.
  • Fred Hutchinson Cancer Center, Seattle, WA.
  • Banner MD Anderson Cancer Center, Gilbert, AZ.
  • Moores UC San Diego Cancer Center, San Diego, CA.
  • David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL.

ORCID-Profile: William G Wierda, Kathleen Dorritie, Jordan Gauthier, Thomas J Kipps, Peter A Riedell, Mohamed A Kharfan-Dabaja, Nirav N Shah, Abhinav Deol, Shuo Ma, Stephen J Schuster, Usama Gergis, Julie M Vose, Jacob Soumerai, Koen van Besien, Yizhe Chen, Sanhita Sengupta, Pradipta Ray, Tanya Siddiqi

Zitieren

APA

Wierda, W. G., Dorritie, K., Gauthier, J., Nath, R., Kipps, T. J., Riedell, P. A., Eradat, H. A., Kenderian, S. S., Kharfan-Dabaja, M. A., Shah, N. N., Solomon, S. R., Stephens, D. M., Ermann, D. A., Arnason, J., Deol, A., Feldman, T., Andreadis, C., Ghosh, M., Ma, S., …, & Siddiqi, T. (2026). Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. Blood, 148(20), 2462-2476. https://doi.org/10.1182/blood.2026033565

Vancouver

Wierda WG, Dorritie K, Gauthier J, Nath R, Kipps TJ, Riedell PA, et al. Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. Blood. 2026;148(20):2462-2476. doi:10.1182/blood.2026033565

BibTeX
@article{Wierda2026,
  author = {Wierda, William G and Dorritie, Kathleen and Gauthier, Jordan and Nath, Rajneesh and Kipps, Thomas J and Riedell, Peter A and Eradat, Herbert A and Kenderian, Saad S and Kharfan-Dabaja, Mohamed A and Shah, Nirav N and Solomon, Scott R and Stephens, Deborah M and Ermann, Daniel A and Arnason, Jon and Deol, Abhinav and Feldman, Tatyana and Andreadis, Charalambos and Ghosh, Monalisa and Ma, Shuo and Schuster, Stephen J and Gergis, Usama and Vose, Julie M and Soumerai, Jacob and van Besien, Koen and Tuazon, Sherilyn A and Perna, Serena K and Ou, San-San and Ananthakrishnan, Revathi and Rane, Neha and Papp, Eniko and Ansari, Sahar and Thompson, Ethan G and Okal, Abood and Peiser, Leanne and Chen, Yizhe and Sengupta, Sanhita and Ray, Pradipta and Wang, Jixian and Siddiqi, Tanya},
  title = {Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004},
  journal = {Blood},
  year = {2026},
  volume = {148},
  number = {20},
  pages = {2462--2476},
  doi = {10.1182/blood.2026033565}
}
Kostenlos starten →